Suppr超能文献

双相患者锂盐治疗不耐受时换用缓释制剂的临床评估:一项随机临床试验。

Clinical evaluation of switching from immediate-release to prolonged-release lithium in bipolar patients, poorly tolerant to lithium immediate-release treatment: A randomized clinical trial.

机构信息

Global Medical Department, Angelini Pharma S.p.A., Rome, Italy.

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

出版信息

Brain Behav. 2022 Mar;12(3):e2485. doi: 10.1002/brb3.2485. Epub 2022 Feb 9.

Abstract

AIM

The effect of switching from lithium immediate release (Li-IR) to lithium prolonged release (Li-PR) on lithium-induced tremor after 1 and 12 weeks of treatment was evaluated in a randomized, multicenter, open trial, in bipolar patients from the participating sites with a tremor severity ≥2 (Udvalg for Kliniske Undersøgelser [UKU] rating scale) despite optimal lithium titration.

METHODS

The primary endpoint was the evaluation of tremor by means of the UKU scale after 1 week of treatment. Secondary endpoints included manic Young Mania Rating Scale (YMRS) and depressive symptoms (Montgomery-Asberg Depression Rating Scale), a global assessment of the patient's status (Clinical Global Impression), polyuria/polydipsia (UKU item 3.8) and patient-reported outcomes.

RESULTS

Owing to difficulties in including suitable patients the enrollment phase was closed when 73 patients were randomized. Notwithstanding the lower number of patients, in the modified intention-to-treat population (n = 70) the primary endpoint was statistically significant: tremor improved after 1 week in 62.9% in Li-PR group against 20.0% of patients in Li-IR group (p = .0006; two-tailed Fisher's exact test). The difference remained statistically significant after 4 (p = .0031) and 12 weeks (p = .0128). The same analysis performed in the PP population confirmed these results. Among the secondary endpoints, only the factor convenience of the treatment satisfaction questionnaire showed a statistically significant difference between groups. There were no apparent differences in the safety profile of the two formulations.

CONCLUSIONS

This study is the first comparative documentation of a potential benefit of the prolonged-release formulation in reducing the symptom tremor, a well-known adverse effect of lithium therapy. Indeed, the study results should be interpreted taking into account the sample size lower than planned.

摘要

目的

在一项随机、多中心、开放性试验中,评估在锂即刻释放(Li-IR)转换为锂持续释放(Li-PR)后 1 周和 12 周时,锂诱导震颤在最佳锂滴定后仍≥2 分(Udvalg for Kliniske Undersøgelser [UKU] 评分量表)的双相患者中的效果。

方法

主要终点是治疗 1 周后通过 UKU 量表评估震颤。次要终点包括躁狂 Young 躁狂评定量表(YMRS)和抑郁症状(Montgomery-Asberg 抑郁评定量表)、患者状态的总体评估(临床总体印象)、多尿/多饮(UKU 项目 3.8)和患者报告的结果。

结果

由于难以纳入合适的患者,当 73 名患者被随机分组时,入组阶段关闭。尽管患者人数较少,但在修改后的意向治疗人群(n=70)中,主要终点具有统计学意义:在 Li-PR 组中,62.9%的患者在 1 周后震颤改善,而 Li-IR 组中只有 20.0%的患者(p=0.0006;双侧 Fisher 精确检验)。在 4 周(p=0.0031)和 12 周(p=0.0128)时差异仍具有统计学意义。在 PP 人群中进行的相同分析证实了这些结果。在次要终点中,只有治疗满意度问卷的便利性因素在组间具有统计学差异。两种制剂的安全性特征没有明显差异。

结论

这项研究是首次比较性地记录了持续释放制剂在减少锂治疗的已知不良反应震颤症状方面的潜在益处。事实上,应该考虑到低于计划的样本量来解释研究结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0ce/8933786/08f4a428b7bc/BRB3-12-e2485-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验